The content on this site is intended for healthcare professionals only
Dr Matt Seymour discusses how the National Cancer Research Network is acting to build collaborations between UK clinical studies groups and pharmaceutical companies to allow patients to access new therapeutic agents at an earlier stage. Dr Seymour explains how the Experimental Cancer Medicine Network is facilitating the simultaneous operation of phase II studies with clinical trials assessing potential combination therapies, outlines the problems that have emerged and the steps that have been taken to overcome these.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
Durable responses in aRCC, how do we optimise treatment?
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation
